Clinical Trial Update: Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating organ preservation with durvalumab-based immunotherapy in combination with chemoradiation as definitive treatment for early-st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Adenocarcinoma

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Conditions: Esophagus Adenocarcinoma | Phase 2 | Status: RECRUITING